2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).

Danuta M Skowronski, Yuping Zhan, Samantha E Kaweski,Suzana Sabaiduc, Ayisha Khalid,Romy Olsha,Sara Carazo,James A Dickinson, Richard G Mather,Hugues Charest,Agatha N Jassem,Inès Levade, Maan Hasso,Nathan Zelyas, Ruimin Gao,Nathalie Bastien

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin（2024）

引用 0|浏览5

暂无评分

摘要

The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要